Amgen's Q3 earnings showcase robust performance with positive growth in most products and a strong bottom line. However, the recent complete response letter for Prolia and the potential impact of the TREAT study on Aranesp sales are concerns. The stock will likely experience volatility in the short term due to these uncertainties. executors provided mixed signals about the future. 

 [-1]